T-cell engagers mediate deep cell depletion beyond autoimmunity
- 20 May 2026
- journal article
- review article
- Published by Elsevier in Kidney International
- Vol. 109 (6) , 1081-1084
Abstract
No abstract availableKeywords
Funding Information
- Lupus Research Alliance
- Deutsche Forschungsgemeinschaft
- Else Kröner-Fresenius-Stiftung
- Boehringer Ingelheim Stiftung
This publication has 19 references indexed in Scilit:
- B-cell maturation antigen-Targeted T-cell Engager Therapy Combined with B-cell Depletion for Treatment of Refractory HLA SensitizationKidney International, 2026
- BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopeniaThe Lancet, 2026
- Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitisAnnals of the Rheumatic Diseases, 2025
- Long-lived IgE plasma cells persist in secondary lymphoid tissues using a navitoclax-sensitive survival programImmunity, 2025
- CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromesMolecular Therapy, 2025
- Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4+ myasthenia gravisMolecular Therapy, 2025
- One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel diseaseAnnals of the Rheumatic Diseases, 2025
- Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantationAnnals of the Rheumatic Diseases, 2025
- Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney TransplantationKidney International Reports, 2024
- Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case studyEuropean Journal of Cancer, 2024